Equity markets have shown resilience amid economic uncertainty, with the S&P 500 gaining 7% year-to-date. However, as fresh concerns loom, investors may want to consider quality dividend stocks to hedge against potential volatility. Two standout options are Amgen (AMGN) and Merck (MRK), both offering attractive yields and robust business fundamentals.
Amgen is navigating biosimilar competition while maintaining growth through a diverse product lineup, including treatments for asthma and thyroid eye disease. With a strong pipeline and a history of increasing dividends—currently yielding 3%—Amgen is positioned for solid financial performance. Similarly, Merck is preparing for the eventual patent expiration of its blockbuster drug Keytruda by expanding its pipeline and diversifying its offerings, including a promising new pneumonia vaccine. Merck also boasts a 3% yield, having increased payouts significantly over the past decade.
For market professionals, both Amgen and Merck represent compelling income-oriented investments that not only provide regular dividends but also possess the potential for long-term growth, making them worthy of consideration in a balanced portfolio.
Source: fool.com